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Is muscle failure a better term than sarcopenia?
Skeletal muscle is a complex tissue, important for locomotion,
bone health, neuromuscular function, metabolism, as well as
a reservoir in catabolic conditions e.g. surgery, infection,
cancer, and trauma.1,2 Despite the aetiological differences
between sarcopenia and cachexia, low muscle mass is an in-
dependent risk factor for frailty, falls, fractures, and mortality
in old age as well as a wide range of acute and chronic dis-
eases affecting millions of people.1,2
The last two decades, the field of sarcopenia research has
evolved dramatically and likewise the number of definitions
and discussions about what it should include. Initially, the
term sarcopenia was solely referring to low lean mass de-
fined as 2SD below the normal mean of a young reference
population.3 Combining measures of lean mass with cut-off
points for muscle strength (hand-grip strength, knee-
extensor muscle strength) and physical function (gait speed,
sit-to-stand test) has not simplified the number of ways
the definition is used or interpreted. Consequently, the
prevalence of sarcopenia is known to vary noticeably,
depending on the studied population, measurements, and
cut-off points used.4
An ongoing discussion within the interest field of
sarcopenia is what assessments should be included, and the
lack of agreement is probably due to the diverse backgrounds
of the researchers involved, ranging from epidemiology to
muscle physiology and cell biology.1,2 From a more pragmatic
point of view, it makes sense to include the most sensitive
and simple measurements that predict sarcopenia.5 How-
ever, we overlook many patients with some degree of muscle
dysfunction if we simplify the assessments to a questionnaire
and/or a measurement of hand-grip strength.
Alternatively, we could accept the complexity of skeletal
muscle health being a combination of sufficient muscle tissue
and neuromuscular function translating into muscle strength,
muscle power, and physical performance and use the term
Muscle Failure as an umbrella term for low muscle mass
(sarcopenia), low muscle strength (dynapenia), and compro-
mised physical function.
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Figure 1 Muscle Failure web for clinical use to diagnose and monitor the different domains of muscle failure. Relative values (per cent of normal) as
well as 1SD and 2SD below young reference. Blue dotted lines is an example of values from a 81 yr old woman from an outpatient clinic.
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At this point in time, we believe that a distinction between
different domains of muscle dysfunction would have a huge
impact on the way we treat patients of all ages with muscle
failure (Figure 1), enabling targeted individualized treatments
to increase muscle mass, muscle strength, or physical func-
tion or a combination of it.
In line with heart failure, a more sophisticated approach di-
agnosing the type, cause, and stage of muscle failure could
then guide individualized non-pharmacological and pharma-
cological interventions.
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